Breast Cancer Molecular Cytogenetics
  • Frederic M. Waldman
Conference paper


The development and progression of breast cancer is a multistep process, the result of a series of genetic alterations occurring over the lifetime of a tumor. The search for specific alterations associated with the development and progression of breast tumors involves an intensive analysis of known genes and a search for new ones. Cellular oncogenes or tumor suppressor genes may be modified by gene mutation, rearrangement, amplification, deletion, epigenetic changes (such as methylation), other changes in RNA transcriptional regulation or processing, and post-translational modifications, all leading to altered protein function. Much of the recent work elucidating these various pathways is based on the hypothesis that identification of specific changes which occur in individual breast tumors will result in better predictive markers of clinical behavior and response to therapy.


Breast Cancer Comparative Genomic Hybridization Human Mammary Epithelial Cell Altered Copy Number Cellular Oncogene 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Clark G (1996) Prognostic and predictive factors. In: Harris J, Lippman M, Morrow M, Hellman S (eds.) Diseases of the breast. Lippencott-Raven Publishers, Philadelphia, pp. 461–486.Google Scholar
  2. 2.
    Page D, Anderson T (1987) Diagnostic histopathology of the breast. Edinburgh: Churchill Living-stone.Google Scholar
  3. 3.
    Harris J, Lippman M, Morrow M et al. (1996) Diseases of the breast. Philadelphia: Lippencott-Raven Publishers.Google Scholar
  4. 4.
    Nass SJ, Dickson RB (1997) Defining a role for c-Myc in breast tumorigenesis. Breast Cancer Res Treat 44: 1–22.PubMedCrossRefGoogle Scholar
  5. 5.
    Courjal F, Louason G, Speiser et al. (1996) Cyclin gene amplification and overexpression in breast and ovarian cancers: evidence for the selection of cyclin D1 in breast and cyclin E in ovarian tumors. Int J Cancer 69: 247–253.PubMedCrossRefGoogle Scholar
  6. 6.
    Band V (1998) The role of retinoblastoma and p53 tumor suppressor pathways in human mammary epithelial cell immortalization. Int J Oncol 12: 499–507.PubMedGoogle Scholar
  7. 7.
    Graff JR, Herman JG, Lapidus et al. (1995) E-cadherin expression is silenced by DNA hypermethylation in human breast and prostate carcinomas. Cancer Res 55:5195–5199.PubMedGoogle Scholar
  8. 8.
    Pierceall WE, Woodard AS, Morrow JS et al. (1995) Frequent alterations in E-cadherin and alpha- and beta-catenin expression in human breast cancer cell lines. Oncogene 11: 1319–1326.PubMedGoogle Scholar
  9. 9.
    Bautista S, Theillet C (1997) p53 mutations in breast cancer: incidence and relations to tumor aggressiveness and evolution of the disease. Pathol Biol (Paris) 45: 882–892.Google Scholar
  10. 10.
    Falette N, Paperin MP, Treilleux I et al. (1998) Prognostic value of P53 gene mutations in a large series of node- negative breast cancer patients. Cancer Res 58: 1451–1455.PubMedGoogle Scholar
  11. 11.
    Somerville JE, Clarke LA, Biggart JD (1992) c-erbB-2 overexpression and histological type of in situ and invasive breast carcinoma. J Clin Pathol 45: 16–20.PubMedCrossRefGoogle Scholar
  12. 12.
    Allred DC, O’Connell P, Fuqua SA et al. (1994) Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Treat 32:13–18.PubMedCrossRefGoogle Scholar
  13. 13.
    Lynch BJ, Guinee DG Jr., Holden JA (1997) Human DNA topoisomerase H-alpha: a new marker of cell proliferation in invasive breast cancer. Hum Pathol 28: 1180–1188.PubMedCrossRefGoogle Scholar
  14. 14.
    Freije JM, MacDonald NJ, Steeg PS (1998) Nm23 and tumour metastasis: basic and translational advances. Biochem Soc Symp 63: 261–271.PubMedGoogle Scholar
  15. 15.
    Kallioniemi A, Kallioniemi OP, Sudar D et al. (1992) Comparative genomic hybridization for molecular cytogenetic analysis of solid tumors. Science 258: 818–821.PubMedCrossRefGoogle Scholar
  16. 16.
    Collins C, Rommens JM, Kowbel D et al. (1998) Positional cloning of ZNF217 and NABC1: genes amplified at 20ql3.2 and overexpressed in breast carcinoma. Proc Natl Acad Sci U S A 95: 8703–8708.PubMedCrossRefGoogle Scholar
  17. 17.
    Tanner MM, Tirkkonen M, Kallioniemi A et al. (1996) Independent amplification and frequent co-amplification of three nonsyntenic regions on the long arm of chromosome 20 in human breast cancer. Cancer Res 56: 3441–3445.PubMedGoogle Scholar
  18. 18.
    Nishizaki T, DeVries S, Chew K et al. (1997) Genetic alterations in primary breast cancers and their metastases: direct comparison using modified comparative genomic hybridization. Genes Chromosomes Cancer 19:267–272.PubMedCrossRefGoogle Scholar
  19. 19.
    Isola JJ, Kallioniemi OP, Chu LW et al. (1995) Genetic aberrations detected by comparative genomic hybridization predict outcome in node-negative breast cancer. Am J Pathol 147: 905–911.PubMedGoogle Scholar
  20. 20.
    Pinkel D, Segraves R, Sudar D et al. (1998) High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays. Nat Genet 20: 207–211.PubMedCrossRefGoogle Scholar
  21. 21.
    Pollack JR, Perou CM, Alizadeh AA et al. (1999) Genome-wide analysis of DNA copy-number changes using cDNA microarrays. Nat Genet 23:41–46.PubMedCrossRefGoogle Scholar
  22. 22.
    Perou CM, Jeffrey SS, van de Rijn M et al. (1999) Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 96:9212–9217.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag New York, Inc. 2001

Authors and Affiliations

  • Frederic M. Waldman

There are no affiliations available

Personalised recommendations